RandyW Posted June 27, 2006 Share Posted June 27, 2006 Helix BioPharma to present L-DOS47 lung cancer research findings at Zurich conference AURORA, ON, June 26 /CNW/ - Helix BioPharma Corp. (TSX: HBP), a developer of novel cancer therapeutics, today announced that Dr. Heman Chao, VP Research, will be presenting a poster at the 5th Annual Congress on Recombinant Antibodies Conference, in Zurich Switzerland. The poster entitled "L-DOS47 - a novel lung adenocarcinoma specific immuno-conjugate therapeutic", highlights the ability of L-DOS47 to target and kill lung tumour cells in vitro and in tumour bearing mice, as well as L-DOS47's ability to enhance the effect of weakly basic chemotherapeutics. L-DOS47 is the first immuno-conjugate therapeutic candidate derived from Helix's novel anti-cancer DOS47 platform technology. The poster further highlights L-DOS47's ability to bind specifically to human lung adenocarcinoma as shown by tissue specific staining. Imaging studies using A549 xenografts and intravenously administered labelled L-DOS47 showed that the drug molecule preferentially accumulated at the tumour site and persisted at the site for more than 72 hours, consistent with strong antibody binding. In addition, in vitro experiments showed that L-DOS47 potentiated the cytotoxic effect of a number of chemotherapeutics. In some instances, less than one tenth of the normal drug dose was required to achieve the desired inhibition of cell growth. "These early findings provide further evidence of the specific nature of the targeting antibody in our immuno-conjugate, as well as provides evidence that L-DOS47 may have the ability to enhance the action of currently marketed chemotherapeutic products," said Dr. Don Segal, President and CEO of Helix BioPharma Corp. "They are encouraging and suggest that L-DOS47 may have potential as a lung cancer therapy." A copy of the presentation will be available on Helix's website for download (http://www.helixbiopharma.com). During the same conference, Helix's collaboration partner, the Institute for Biological Sciences of the National Research Council of Canada (NRC-IBS) will be presenting research work on the antibody that is used in L-DOS47. Dr. Jianbing Zhang of NRC-IBS has been selected by the organizing committee to give an oral presentation entitled "ES1, A pentabody with novel specificity to non-small cell lung carcinoma." The 5th Annual Congress on Recombinant Antibodies Conference is organized by Informa Life Sciences and runs from June 27 to June 30th at the Renaissance Zurich Hotel in Zurich Switzerland. The conference is a premier meeting place for scientists and executives from the biotechnology and pharmaceutical industries, as well as academics, to showcase the latest research innovations related to antibodies and immuno-conjugates for human therapies. About the National Research Council Institute for Biological Sciences (NRC-IBS) Recognized globally for research and innovation, the NRC is a leader in the development of an innovative, knowledge-based economy for Canada through science and technology. The NRC operates world-class research facilities, as well as information, technology and innovation support networks from coast to coast. Its outstanding people help turn ideas and knowledge into new products, processes and services, creating value for Canada. The NRC works hand in hand with partners from industry, government and universities to help ignite the spark of innovation in communities across the land and to give Canadian companies a competitive edge in today's marketplace (www.nrc-cnrc.gc.ca). With over 75 years of research excellence, the NRC Institute for Biological Sciences (NRC-IBS) consists of a team of leading life science researchers dedicated to spearheading the next breakthrough discoveries and technologies in neurobiology, immunobiology and glycobiology. Driven by these challenges, NRC-IBS is focused on innovative research of interest to the healthcare and pharmaceutical sectors. About Helix BioPharma Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b, for the treatment of conditions caused by the human papilloma virus, and its novel L-DOS47 new drug candidate. Helix is listed on the TSX under the symbol "HBP". The Toronto and Frankfurt Stock Exchanges have not reviewed and do not accept responsibility for the adequacy or accuracy of the content of this News Release. The presentations referred to in this News Release are subject to change or cancellation without notice. Helix BioPharma Corp. ("Helix" or the "Company") has relied solely on NRC-IBS for the information about NRC-IBS provided in this News Release and the Company disclaims any liability with respect to such information. Helix disclaims responsibility for information contained in any linked or referenced website, and such links and references do not constitute an endorsement by Helix of those or any other website. This News Release contains certain forward-looking statements regarding the Company's research and development initiatives and in particular, L-DOS47, which statements can be identified by the use of forward-looking terminology such as "may", "encouraging", "potential", "suggest", "will", or comparable terminology referring to future events or results. Forward looking statements are statements about the future and are inherently uncertain, and Helix's actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous factors, including without limitation, uncertainty whether DOS47 or L-DOS47 will be successfully developed as a drug or otherwise commercialized; the need for additional research and development, the outcome of which is uncertain; the need for clinical trials, the occurrence and success of which cannot be assured; product liability and insurance risks; the risk of technical obsolescence; the need for regulatory approvals, which may not be obtained in a timely matter or at all; intellectual property risks; marketing/manufacturing and partnership/strategic alliance risks; the effect of competition; Helix's need for additional future capital, which may not be available in a timely manner or at all; as well as a description of other risks and uncertainties affecting Helix and its business, as contained in news releases and filings with the Canadian Securities Regulatory Authorities, any of which could cause actual results to vary materially from current results or Helix's anticipated future results. Forward-looking statements are based on the beliefs, opinions and expectations of Helix's management at the time they are made, and Helix does not assume any obligation to update any forward-looking statement should those beliefs, opinions or expectations, or other circumstances change. For further information: Investor Relations: Nick Hurst, The Equicom Group Inc., Tel: (416) 815-0700 ext. 226, 1-800-385-5451, Fax: (416) 815-0080, Email: firstname.lastname@example.org; Media Relations: Matthew Haines, Noonan Russo, Tel: (212) 845-4235, Fax: (212) 845-4260, Email: Matthew.Haines@eurorscg.com; www.NoonanRusso.com Quote Link to comment Share on other sites More sharing options...
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.